A system for opening a medical blister package

[0001] The invention relates to a system for opening a medical blister pack.

BACKGROUND OF THE INVENTION [0002] Physiological requirements vary from person to person and even within a person's life cycle. In addition, various conditions may affect physiological requirements. For example, a pregnant, breastfeeding or menopausal woman may have an increased need for specific nutrients, therapeutic agents or medications, and reduced needs or even tolerance to other nutrients, therapeutic agents or medications. Meeting the specific physiological requirements of humans and other animals may require a complex daily treatment regimen involving the administration of various biologically active substances at different times of the day.

[0003] The WHO study estimated that only 50% of patients suffering from chronic diseases in developed countries follow the treatment recommendations. This can affect patient health and society if it causes complications associated with chronic diseases, the emergence of refractory infections or untreated psychiatric diseases.

[0004] Many factors play a role in poor patient compliance, including the complexity of the treatment regimen, unclear drug delivery instructions, unclear treatment purpose, forgetfulness, and physical difficulties in following the regimen, e.g., opening drug containers.

[0005] The problem of non-compliance is even greater when the treatment regimen is complex, requiring multiple doses per day, treatment period or different doses of combined drugs. Avoiding strict treatment regimens can lead to reduced effectiveness of therapeutic treatment. Conversely, careless administration of medications can increase the severity of unwanted side effects and exposure to unjustified safety risks, including death. Disposable pharmaceutical containers for dispensing medications that help patients to improve their compliance have already been disclosed.

[0006] To assist patients in improving compliance with the treatment regimen and switching to patient compliance in one common approach, markings embossed or printed on the blister pack are used.

[0007] US 2007015728 provides a dispenser package for co-administering the first and second components of a therapeutic agent. The dispenser package includes a first group of multiple non-contacting chambers, each containing a particular dose of the first component, and a second group of multiple chambers, each of which can reversibly receive at least one dose of the second component.

[0008] US 6,375,956 relates to a disposable dispensing apparatus providing optimal therapeutic support to humans and other animals by conveniently providing a complex dosing regimen requiring the simultaneous administration of incompatible storage ingredients or unequal doses in a stable and user-friendly form.

[0009] WO04089274 relates to the packaging of a medicament, kit or presentation facilitating self-medication by a patient, which is characterized by containing one or more blisters with instructions for the patient in printed form, among others regarding the dosage of each unit, type or maturity of the active ingredient, time of admission and treatment period, along with other information.

[0010] US 2004266745 discloses a blister pack for preparations useful in hormone replacement therapy, in which the system facilitates the alternative administration of a daily unit dose, preferably as a scheme using integers from 1 to 28 to record the sequence of a particular unit dose for administration each day.

[0011] US2007015839 discloses a daily drug delivery regimen for treating metabolic syndromes in a single package. The pack contains acceptable doses at two different times of the day. The packaging may include a one or many day schedule.

[0012] Other approaches have been disclosed to assist patients in improving treatment compliance.

[0013] US 4,627,432 relates to a drug delivery device for patients comprising a cylindrical chamber containing a support for supporting the blister pack. The blisters are placed in holes in the support. The pusher of the button goes into the chamber and opens the associated blister. After opening the blister, the patient can take the medicine.

[0014] US 4,850,489 relates to dispensing packages comprising chambers with at least two fixed dispensing units that are not mechanically connected. Depending on the needs, two contained drugs can be released at certain intervals.

[0015] US2001030140A discloses a blister pack for pharmaceutical treatment with a plurality of separate blisters suitable for containing a pre-measured dose of a pharmaceutical composition in the form of tablets, pills and capsules. According to the pre-defined administration scheme, the sealed blisters can be opened by peeling (org .: tearing), peeling (org .: peeling) and pushing.

[0016] US 4,889,238 relates to a drug package for improving compliance with a treatment regimen. The treatment regimen includes many drugs administered to patients in the prescribed sequence and at specific intervals. The pack contains a plurality of blisters with the medicines in sequential order on and off the separate blisters. The blisters are stacked so that their basic dimension is directed horizontally generally and arranged in the order of use with the first one to be used at the very top. Also included is a base housing a stack of blisters adapted to hold the stack vertically and provide lateral support to the edges of the blisters. The base allows direct and unrestricted access to the topmost blister and limited access only to the edges of the blisters. The lid is adapted to close the base and move to an open position, providing access to the blister located at the very top. Generally, each blister contains indications indicating the order and sequence of administration of the contents of individual wells in the blister.

[0017] WO9822072A describes a pharmaceutical package for assisting or improving the patient's compliance with a particular pharmaceutical drug regimen comprising: a) at least one blister divided into parts separating each dose of the combined dosage regimen; each dose contains an indication indicating the time of dosing; b) a patient information leaflet with dosing information; c) a daily calendar containing dosage information; id) reminder.

[0018] US 4,254,871 relates to a packaging element for attaching blister strips containing a series of medicaments for a patient. The element comprises a folded thin sheet divided into a supporting and covering element, which element is characterized by a plurality of holes for blister strips. The plaque is marked so that it shows the day of administration of the contents of each strip to improve patient compliance.

[0019] WO 03079959 relates to a tablet box for receiving and withdrawing tablets in a controlled manner. The commercially available blister pack can be placed directly in the tablet cup, which is provided with an alarm display1 for removing the tablets.

[0020] US 2002162769 discloses a pre-packaged treatment regimen comprising two unit doses. The disclosed pharmaceutical dosage container includes markings for distinguishing between the first and second unit doses, and instructions for teaching teaching about the coordinated use of unit doses.

[0021] EP1502568 relates to an assembly for dispensing pharmaceutical products comprising perforated plates with a casing connected to an electronic box, where the blister pack is placed in the assembly is on the contacts for closing the circuit, and the perforated swinging blade acts as a lid and selectively blocks the blisters in the package. An audible and visual alarm is generated at the same time each day according to the instructions on the blister pack, reminding the patient to follow the scheme.

[0022] WO 2004/031050 relates to an improved blister pack with a tray containing a recess for e.g. tablets or capsules. The packaging is characterized by a manually removable sheet partially attached to the top layer of the tray. The unattached part has a graduated tab for easy gripping and peeling of the sheet by the patient.

[0023] The pharmaceutical holders, dispensers and pharmaceutical packaging discussed above do not have certain aspects. Significantly, none of the above references provides a convenient, simple and effective way to facilitate selective access and thus administration of a substance, especially when the substances are taken as part of a complex, time-dependent sequential therapeutic regimen. In addition, none of the above references discuss how to facilitate the simultaneous administration of prescription and over-the-counter substances as part of a complex regimen. Furthermore, none of the above references discuss the issue of optimizing pharmaceutical packaging and assisting patients in adhering to treatment. Therefore, simple, inexpensive and convenient means are needed to provide optimal therapeutic support to humans and other animals, and especially to provide optimal support to humans and other animals with special therapeutic needs.

[0024] Furthermore, nothing in the prior art solves the problem of providing security in a package. The state of the art does not provide a solution to the problem of accidental misuse, e.g. patients may have access to the medication and thus take it in the wrong order.

[0025] Therefore, a simple and effective system is needed to increase the safety and effectiveness of compliance with the regimen by imposing prescribed doses at specific intervals for the drugs included in the treatment regimen.

OBJECT OF THE INVENTION [0026] The object of the invention is to provide a system to assist patients in improving compliance with a treatment regimen. Another object of the invention is to provide a system to assist patients in ensuring safety and efficacy by following a treatment regimen.

[0027] Another object of the invention is to provide an alternative to the prior art.

[0028] In particular, it may be an object of the invention to provide a system that solves the above prior art problems by providing selective access to the blister pack according to the preferred opening sequence.

SUMMARY OF THE INVENTION [0029] The object of the invention is directed to a storage-stable disposable dispensing system and dispensing apparatus that provide optimal therapeutic support while overcoming the shortcomings of currently available pharmaceutical packaging in a simple, effective, convenient and economical way.

[0030] Therefore, the above purpose, and many others, are intended to be achieved in the first aspect of the invention by providing a system for opening a package comprising a carrier sheet with at least two separate cavities adapted to contain pharmaceutical compositions and at least two overlapping each other with covering sheets, each covering at least one cavity containing elements characterized by that access to one element is obtained by removing the preceding overlapping cover sheet and by the fact that access to subsequent elements is obtained after sequential removal of the corresponding preceding, overlapping covering sheets.

[0031] The system allows opening of packages formed by a carrier sheet comprising at least two cavities covered with separate cover sheets. Covering sheets overlap predetermined areas, limiting the elements that can be caught and peeled off or torn off by pulling them up and back to provide access to a corresponding recess located on the underlying carrier sheet. Removing the first cover sheet by peeling or tearing off the cover sheet or catching the element connected thereto provides access to the first cavity and to the second element, which in turn can be peeled off or detached to provide access to the second cavity and its contents and the second element and so on. Removal of the cover sheets can be obtained in a predetermined and defined sequential manner determined by the overlapping of the cover sheet limiting the elements. The advantage is to provide access to the contents of the respective wells in a desired and predetermined sequential manner.

[0032] Sequential is defined as occurring as a regular sequence, while the preceding one is defined as the previous following in a specific spatial order, e.g. the top covering sheet precedes the direct bottom overlapping sheet. Therefore, access to the first element is obtained by removing the first cover sheet by a specific action, e.g. peeling or tearing off the cover sheet or the gripping element connected thereto and access to the second element is obtained by removing the second covering sheet by a specific action, e.g. peeling or tearing off the first element and so on.

[0033] The element at least partly limited by the overlapping of the cover sheets may be in the form of a tab, strip, scrap, notch or flap. The element is characterized in that it is at least partially unadhesive or not strongly adhered to the carrier sheet. It has a function that provides better grip for the user to peel or tear off the cover sheet and gain access to the cavities. The form, dimension and shape of the element are related to its function. The element can have any form and size that can be caught by man or mechanically. The shape of the element can be in any geometric form or a combination thereof, e.g. triangular, round or square. In some embodiments, the elements may have a user-friendly shape, e.g., like a pad, to provide better user retention when using.

[0034] In some embodiments, the element may be made of a non-slip material, such as rubber, or may have some degree of surface unevenness to provide better grip.

[0035] The elements may be located at different locations along the edges of the cover sheets.

[0036] In some embodiments, the element is a flap that may have protrusions to provide better grip. The protuberances can be embossed or printed. Information printed on the damper element may also be in the form of relief.

[0037] In some embodiments, the package may be a blister package, where the recesses are in the form of blisters. In some other embodiments, the package may be a medical blister pack in which the depressions of the carrier sheet comprise a pharmaceutical composition.

[0038] The previously described object and many other purposes are intended to be realized in the second aspect of the invention, providing a blister pack comprising a carrier sheet with at least two separate cavities adapted to contain pharmaceutical compositions and at least two covering sheets, each of which covers at least one a recess in which at least two covering sheets are at least partially glued (org .: sealed) to the carrier sheet around at least two depressions, and at least two covering sheets overlap and limits at least two elements characterized in that access to one element is obtained by removing the preceding overlapping covering sheet and in that access to subsequent elements is obtained by sequential removal of suitably preceding overlapping cover sheets.

[0039] The blister pack, e.g. the medical blister pack, comprises a carrier sheet with cavities and is characterized in that access to the element that allows access to the next cavity is hindered by the previous element so that access to the next cavity is only possible after access to the previous recess. Accordingly, the dosage of individual pharmaceutical compositions is only possible in a predetermined sequential manner.

[0040] The carrier sheet of the blister pack may be made by extrusion, casting, deep drawing or vacuum forming of plastic, plastic laminate, plastic laminate / paper, plastic laminate / metal foil or metal. Non-limiting examples of suitable plastics for the carrier sheet are PVC-containing films and laminates, polyamides, polyolefins, polyesters, polycarbonates and combinations thereof. The carrier sheets may also contain a barrier layer against gases, vapors and light. Such barrier layers may be a metal foil, such as aluminum foil extruded in a plastic laminate, or suitably ceramic layers or metal layers extruded between two layers of plastic. Ceramic layers can be produced by evaporating metals, oxides or nitrides of aluminum, silicon and other metals and semi-metals in a vacuum and settling the substance on a plastic substrate. These methods are known as chemical vapor deposition and physical vapor deposition or spraying. The ceramic layers may preferably contain aluminum oxides or silicon oxides or may be mixtures of different oxides, and if desired also mixed with metals such as silicon or aluminum. Metal layers can be created by evaporating metals in a vacuum and depositing them on a plastic substrate; aluminum layers are given here as an example. The plastic substrate can be a plastic film or a plastic base made of the above-mentioned plastics.

[0041] The material of the cover sheet may be made of a metal foil, such as aluminum foil or a laminate comprising aluminum foil. Aluminum foil can be replaced with plastic foil, plastic laminates, plastic / paper laminates or plastic / metal foil laminates. Aluminum foil can also be replaced with plastic showing low elasticity and poor stretching properties. Plastic material with these properties can be obtained by adding a large amount of filling material to the plastic.

[0042] In this sense, filler is defined as particles of material added to a plastic material to provide properties that differ from those of the plastic itself.

[0043] In some embodiments, the cover sheet may comprise at least two films, e.g., a first film, such as aluminum foil, or a laminate, comprising aluminum foil, and a second film, such as adhesive tape. The adhesive tape has the function of removing at least a portion located below the first film to provide access to a suitable cavity after the desired sequential opening. The overlap of multiple adhesive tapes can produce the desired sequential opening on a single first film. For example, all the recesses can be covered with a single first foil, such as aluminum foil. A series of separate adhesive tapes overlapping the predetermined areas can act as a cover sheet as described above. Separate adhesive tapes can overlap, limiting the elements that can be gripped, peeled off or torn off, pulling up and back, causing the removal of the first film, e.g. aluminum foil, obstructing access to the respective depressions on the underlying carrier sheet. Removing the first adhesive tape by peeling or tearing off the adhesive tape or the gripping element connected thereto removes the area of ​​the first film located on the first cavity; in fact providing access to the first cavity. In this way, the second element, which in turn can be peeled off or peeled off, causing the adhesive film to remove an area of ​​the first film disposed on the second cavity; in fact providing access to the second cavity and its contents and the second element and so on. Generally, sequential opening can be obtained by removing the adhesive tape in a predetermined and specific sequential manner determined by the overlap of the adhesive tapes.

[0044] The carrier sheet usually has a plurality of cavities in the form of cups or dishes without restrictions.

[0045] In some other embodiments of the invention, the cavities in the carrier sheet can be obtained by calendering, casting, injection molding or other known thermoplastic processes. The recesses may be surrounded by an edge, which edges together form a joined flat plane. The carrier sheets are prepared, for example, as an endless strip with the contents in the recesses and placed together with the cover sheet material, in particular in foil form, as in the form of an endless strip. Covering sheets completely cover the carrier sheet and, for example, by sealing or gluing are connected to the carrier sheet at the edges. Covering sheets can be sealed or glued to the edges of the entire area or by choosing a special sealing tool or adhesive pattern designed for this purpose, while sealing or gluing can only be partial. For example, the endless strip of carrier sheet sealed to cover sheets can be cut to the desired size. This can be done, for example, using a press. At the same time, the blister pack may have outer contours or it is possible to provide weakness in the cover sheets or carrier sheet to allow the blister pack to bend or to form lid segments, facilitating removal of the cover sheets and contents.

[0046] The day markings may also be included in the blister pack according to the invention. The markings can be of various types without restrictions. The day markings correspond to at least two different recesses on the carrier sheet. For example, without limitation, the day designation can be a specific day of the week such as Monday, Tuesday, Wednesday, Thursday, Friday, Saturday and Sunday or an abbreviation of the day, a specific date or a general sequence of days, such as day 1, day 2, day 3 and so on. Indications of the day may be marked directly on the pharmaceutical composition or other part of the blister pack.

[0047] The time stamp may also be included in the blister pack according to the invention. The time stamp can be of any type without limitation. The time stamp corresponds to at least two different periods of time, but may correspond to any number of different periods of time without limitation. For example, without restrictions, a time stamp may indicate the general time of day or a specific time of day. For non-limiting examples, general times of the day may be, for example, one of the following: morning, afternoon, morning, afternoon, evening, day, night, daytime, nighttime and combinations thereof. Each separate row or column of the blister pack may each indicate the time of day, such as the morning dose and afternoon dose of the drug. The predefined area of ​​the blister pack can be color-coded for time. The blister packaging may additionally include a key defining or explaining the color marking. For example, without limitation, the area around the well containing the pharmaceutical composition to be taken in the morning may be orange, while the areas containing the well containing the pharmaceutical composition to be taken in the afternoon may be blue. In addition, the cavity containing the pharmaceutical composition may be directly color coded. For example, each well containing the pharmaceutical composition for administration in the morning may be marked in yellow, and the well containing the pharmaceutical composition for administration at night may be marked in red without restrictions. In addition, each individual pharmaceutical composition may be individually marked with a color to indicate time. Each cavity may be made of a transparent or translucent material such that the color marking on the pharmaceutical composition can be seen when the pharmaceutical composition is in the cavity. For example, each well containing morning doses may be marked green and clearly visible in the blister pack. Alternatively, the recess may be an opaque shade of color. A color key can be provided on the blister pack to indicate which color corresponds to the date or time of the composition. The marking provides a reliable and effective feedback system such that the patient can determine if the correct doses have been taken on the right days and at the right times by comparing the marking on the packaging with the calendar or clock.

[0048] The invention is particularly, but not exclusively, beneficial for providing safety in patient compliance with the treatment regimen. Since access to the wells containing the pharmaceutical compositions is only possible, following a predetermined sequential order, accidental misuse due to patient errors is minimized. For example, patients with vision problems, e.g. people with severe visual impairment may not always be able to identify the mark on the packaging and therefore may accidentally take the medicine in the wrong order. In the case of the blister pack according to the invention, only a predetermined and desired opening sequence is possible, and therefore safety of compliance with the treatment regimen is achieved. Pharmaceutical compositions that may benefit from the advantages of the invention may also be contraceptives or medications for chronic diseases that often require sequential tablet intake for optimal efficacy. The invention can provide security in following the treatment regimen because in the case of the packaging according to an embodiment of the invention the wrong acceptance sequence due to the wrong opening sequence is not achievable.

[0049] The pharmaceutical composition may contain any biologically active substance without restrictions. Preferably the unit doses of the invention contain vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, essential fatty acids, folic acid, iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron , selenium, manganese, their derivatives and combinations thereof. Non-limiting exemplary biologically active substances according to an embodiment of the invention may include thiamine, thiamine pyrophosphate, riboflavin, flavin mononucleotide, flavin-adenine dinucleotide, niacin, nicotinic acid, nicotinamide, niacin amide, nicotinamide dinucleotide, adotinic acid, tryptophanic acid, tryptophanic acid retinol, retinal, retinoic acid, beta-carotene, 1,25-dihydroxycholecalciferol, 7-dehydrocholesterol, alpha-tocopherol, tocopherol, tocotrienol, menadione, menaquinone, phylloquinone, kerosene quinone, calcium, calcium carbonate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, calcium malate, calcium gluconate, calcium lactate, calcium phosphate, calcium levulinate, phosphorus, potassium, sulfur, sodium, sodium docusate, chloride, magnesium, magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium sulfate, copper, iodine, zinc, chromium, molybdenum, iron carbonyl, iron fumarate, polysaccharide iron, combinations and derivatives thereof without restrictions. Non-limiting exemplary derivatives of vitamin compounds include salts, alkali salts, esters and chelates of any vitamin compound.

[0050] The pharmaceutical compositions may be prescription or non-prescription substances or drug excipients for use in prescription or non-prescription substances. Non-limiting examples of prescription substances include 13 C-urea (Helicobacter test), 15-methyl-prostaglandin F2a, 1a-hydroxyvitamin D3, 2,4-dichloro-benzyl alcohol, 5-aminolevulinic acid hydrochloride, aminolevulinic acid (5-ALA), abacavir / lamivudine , abacavir / lamivudine / zidovudine, abatacept, abciximab, acamprosate, acarbose, acebutolol, acepromazine, acetaminophen, acetate, acetazolamide, acetophenazine, acetylcysteine, acetylsalicylic acid, acyclovir, acipimox, acitretin, acrivastine, acyclovir, adalimumab, adapalen, adefovir dipivoxil, adenosine, adrenaline, esculin, agalsidase alpha, beta agalsidase, agomelatine, alanine, human albumin, aldesleukin, alemtuzamb, alendronate, alcalcerferal acid alfentanil, alfuzosin, alginic acid, alpha alglucosidase, alimemazine, aliskiren, aliskiren hemifumarate / hydrochlorothiazide, alitretinoin, allopurinol, almitrine, almotriptan, alprazolam, alprenolol, alprostadil, alteplase, aluminum aminoacetate, aluminum hydroxide, sucrose aluminum sulfate, bases, amantadine, ambenonium, ambrisentan, ambroxol, amfepramon, amidotrizoate, amiloride, aminophilyin, aminoglutethimide, aminosalyl, amsilipilin / hydrochlorothiazide, amlodipine / valsartan besylate, amlodipine / valsartan, amorolfine, amoxicillin, amphotericin B, ampicillin, amprenavir, amsacrine, amylase, amylmetacresol, anagrelide, anakinra, anastrozole, anidulafungin, antazoline, antithrombin, antithrombin alpha, antithymocytic globulin, apomorphine, apraclonidine, aprepitant, aprotinin, arcitumomab, argatroban, arginine, aripiprazole, arseparin, atsenicin, articaine, atorvastatin, atosiban, atovaquone, atropine, auranofin, aurothiomalate, aviptadil, azacitidine, azacytidine, azapropazone, azathioprine, azelaic acid, azelastine, azetazolamide, azithromycin, aztreonam, azteonam, human C1 esterase inhibitor, bacampicillin, bacillus Calmette Guerin (Danish strain 1331), bacillus Calmette Guerin (RIVM strain derived from strain 1173-P2), baclofen, balsalazide, bamboouterol, barbeximine, basilexx , beclometasone, beclometasone dipropionate, benazepril, bendroflumethiazide, benzatropine, benserazide, benzylpenicillin, benzalkonium chloride, benzocarboxylic acid, benzenomethanol, benzocaine, benzoic acid, benzoyl peroxide, benzadymine, penzylpenicillin, beta carotene, betahistine, betaine, anhydrous betaine, betamethasone, betamethasone-17-valerate, betamethasone-21-acetate, betamethasone dipropionate, betamethasone phosphate, betanidine, betaxolimate, bicalacetone / timolol, biotin, biperiden, bisacodyl, bisprolol fumarate, bivalirudin, black rubber mixture (PPD mixture), bleomycin, borax, bortezomib, bosentan, botulinum toxin type A, botulinum toxin type B, brimonidine, brimonidine tartrate, brinzolamide, brinzolamide / timolol, bromazepam, bromhexine, bromocriptine, bromfeniramine, budesonide, bumethanide, bupivacaine, buprenorphine, buprenorphine, busboxonone, naloxone iodine, caffeine, a mixture of cain, calcipotriol, calcitriol, calcitonin, calcitonin (salmon), calcium, calcium acetate, calcium carbonate, calcium chloride, calcium fluoride, calcium folinate, calcium gluconate, calcium lactogluconate, calcium polystyrenesulfonate, canakinumab, candesartan cilexetil, capecitabine, capsaicin, captopril, carbamazepine, carbba mixture, carbetocin, carbidopa, carbimazole, carbomer, activated carbon, carboplatin, carboprost, carglumic acid caspofungin, catumaxomab, cefalexin, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, celecoxib, cefaclor, cefadroxil, cefalexin, cephalotin, cefradine, certolizumab pegol, cetirizine, cetrorelix, cetuximab, quinidine, clofibrate, clometiazole, clomiparamine, clonazepam, chlorprothixene, chloralhydrate, chlorambucil, chloramphenicol, chlordiazepoxide, chlorhexidinol, chlorhexazonotchlor, clonazonotropin, cholecalciferol, vitamin D3, choline theophylate, alpha chorionic gonadotropin, human chorionic gonadotropin (hCG), Chorionic gonadotropin - a (hCG), chromium, cyclopirox, cyclopiroxolamine, ciclosporin, cidofovir, cilastatin, cimetidine, cinacalcet, cinchocaine, cinetazone, cinnamaldehyde, cinnamyl alcohol, cinnarizine, ciprofloxacin, cisofloxacinatin , Cl + Me-isothiazolinone (Kathon CG), cladribine, clarithromycin, clavulanic acid, clemastine, clemastine, clindamycin, clioquinol, clobazam, clobetazole propionate, clobetasone-17-butyrate, clodronate, clofarabine, clomiphene, clomipramine, clonazepam, clonidine, clopamide, clopidogrel, clotrimazole, cloxacillin, clozapine, cobalt (II), copper, copper acetate, codeine, colesevelam, colestipol, colestyramine, colistimethalate, corticotoxin, corticotoxin, corticotone B12, ciclanderal, cyclysine, cyclopentolate, cyclofenil, cyclophosphamide, cyproheptadine, cyproterone, cyproterone acetate, cysteamine, cysteine, cystine, cytarabin, cytarabine, dabigatran, etexilate, dacarbazine, daclizumab, dalteparin, dantrone, dapson, daptomycin, darbepoetin alfa, darifenacin, darfenacin, darunavir, dasatinib, daunorubicin, defarazirox, deferiprone, deseroxiline, deserlidine, descarlide as sulfate), desmopressin, desogestrel, desoxymethazone, dexamethasone, dexschlorfeniramine, dexibuprofen, dexketoprofen, dexpanthenol, dexpanthenol, vitamin B5, dexrazoxane, dextan 1, dextran 40, dextran 70, dextromethorphan, dextropropoxyphene, diazepam, diazoxide, dibotermin alfa, dichlorfenamide, diclofenac, diclofenac sodium, dicloxacillin, dicumarol, didanosine, dienogest, digoxin, dihydroxerazine, dihydroxerazine, dipotassium, diltiazem, dimeglumine gadopentetonate, dimenhydrinate, dimethylaminodiphenylbutane, dimethicone, dimethicone, iron fumarate, nitrous oxide, dinoprost, dinoprostone, diosmin, diphenhydramine, diphenoxylate, dipyridamole, disodium clodronate, etridronate disodium, disodium phosphate, disopyramide, disulfiram, dexyrazine, dobutamine, docetaxel, docosahexaenoic acid (DHA), docusan, dofetilid, dorpipil dorzolamide, dosulepin, doxapram, doxazosin, doxepin, doxorubicin, doxorubicin hydrochloride, doxycycline, droperidol, drospirenone, drotrecogin alfa (activated), duloxetine, dutasteride, ebastine, econazol, eculizumab, efalizumab, efavirenz, efavirenz / emtricitabine / tenofovir disoproxil (as fumarate), eflornithine, eicosapentaenoic acid (EPA), econazole, eletriptan, emedastine, emepraprone, emepraprone entacapone, entecavir, ephedrine, epinephrine, epirubucin, eplerenone, epoetin alfa, epoetin beta, epoetiba delta, epoetin zeta, epoprostenol, epotermal alpha, epoxyresin, eprosartan, eptacog alfa (activated), eptifibatide, eptotermin alfa, erdosteine, ergocalciferol, vitamin D2, ergotamine, erlotinib, ertapenem, erythromycin, escitalopram, eslicarbazepine, eslicarbazepine acetate, eslicarbazepine, estradiolol, estradiolate estradiolate estradiol estriol, etambutol, etanercept, etanercept, ethacrynic acid, ethambutol, ethinyl estradiol, ethosuximide, ethylenediamine, ethylmorphine, etidronate, ethylefrine, etodolac, etonogestrel, etoposide, etoricoxib, etravirine, etulose, eugenol, everolimus, exemestane, exenatide, ezetimibe, ezlocillin, factor IX, factor VIII, famciclovir, febuxostat, felodipine, felipressin, phenoterol, fentanyl, iron citrate

ferritetrasemisodium), ferrous salts, iron succinate, ferumoxil, fesoterodine, fexofenadine, fibrinogen, fibronectin, filgrastim, finasteride, fish oil (org .: fiskeolie), flavoxate, flecainide, flucloxacillin, fluconazole, flucytosine, fludarabinophosphate, fludrocortisone, fludrocortisone acetate, flumazenil, flumedroxone, flumetasone pivalate, flunarizoconone, fluunzazoconone, fluonazococinone, acetone , flupentizole, fluphenazine decanoate, fluefenazine, flurbiprofen, flutamide, fluticasone furoinain, fluticasone propionate, fluvastine, fluvoxamine, folic acid, folic acid heparin, follitropin alfa, follitropin beta, follitropin-a (rfSH), follitropin-b (rfSH), fomivirsen, fondaparinux, fondaparinux sodium, formaldehyde, formoterol, fosamprenavir, fosaprepitant dimeglytine, phosphinopine, phosphinopine buckthorn bark, frovatriptan, fulvestrant, furosemide, fusidic acid, gabapentin, gadobutrol, gadodiamide, gadofosfeset, gadoteridol, gadoteric acid (org .: gadoterinsre), gadoversetamide, galantamine, galsulfase, ganciclovir, ganirelix, gefitinib, gelatin, gemcitabine, gemeprost, gemfibrozil, gantamycin, geraniol, gestodene, glatiramer acetate, glibenclamide, gliclazide, glippyramide, glucagon, glucagon, glucagon glutathione, glycerol, glycerol phosphate, glycerol nitrate, glyceryl trinitrate, glycine, glycopyrron, glycylglutamine, glycyl tyrosine, golimumab, goserelin, gramicidin, granisetron, griseofulvin, guanethidine, guanfacine, heloperidol, heparin, heparin cofactor, heparinoid, hesperidine, hexamine levulinate, histamine, histidine, histrelin, human coagulation factor IX, human fibrinogen / human thrombin, human normal immunoglobulin, human normal hydrochloride, hydrochloride , hydrochlorothiazide, hydrocortisone acetate, hydrocortisone, hydrocortisone 17-butyran, hydrocortisone succinate, hydrogen peroxide, hydromorphone, hydroxychloroquine, hydroxyprogresterone, hydroxyzine, hydroxocobalamin, vitamin B12, hydroxycarbamide, hydroxychloroquine, hydroxycitronellal, hydroxyethyl rutoside, hydroxyethyl stivelse starch, hydroxycarbamide, hyoscine, hyoscine butylbromide, hyoscine, hypromellose, and ibandatronic acid ibandronsyre), ibritumomab, tiuxetan, ibuprofen, icatibant, ichtamol, icodextrin, idarubicin, idursulfase, ifosfamide, iloprost, impatinib, imatinib mesylate, imiglucerase, imipenem, imipramine, human immunoglobulin, immunoglobulin , indomethacin, infliximab, inositol niconitan, insulin, insulin aspart, insulin aspart protamine, insulin detemir, insulin glargine, insulin glulisine, human insulin (rDNA), insulin lispro, insulin lispro with protamine suspension, human insulin, isofranic human insulin, interferon alfa-2b, interferon alfa-1, interferon beta-1a, interferon idoxuridine, interferon-alfa, interferon-alfa-2b, interferon-beta-1a, interferon-beta -1b, interferon-gamma-1b, interleukin-2, iobitridol, iodine (org .: iodidine), iodixanol, ioflupane (123 L), iohexol, iomeprol, iopromide, iotrolan, iowersol, ipratropium, irbesartan, irbesartan / hydrochlorothiazide, irinotecan, isocarboxazide, isoeugenol, isoflurane, isofasin, isofasin, isoleucine, isosorbide mononitrate, isotretinoin, isradipine, itraconazole, ivabradine, ketobemidone, ketobemidone, ketoconazole, ketoprofen, ketorolac, ketotifen, Colophon, creatinine monohydrate, creatinine monohydrate, labetaline lacidipine, lacosamide, lactate, lactic acid, bacterial lactic acid, lactulose, lamivudine, lamivudine / zidovudine, lamotrigine, lanolin, lantreotide, lansoprazole, lanthanum, lapatinib, laronidase, laropiprant, lazophenofloxofloxyfloxifen Lepirudin, Lercanidipine, Letrozole, Leucine, Leucovorin, Leuprorelin, Levetiracetam, Levocabastine, Levocetirizine, Levodopa, Levofloxacin, Levofolic Acid, Levomepromazine, Levonorgestrel, levothyroxine, lidocaine, lincomycin, linezolid, lyothyroin, lipase, liraglutide, lisinopril, lithium carbonate, lithium citrate, lodoxamide, lofepramine, lomustine, loperamide, lopinavir, loratadine, lorazepam, lormetazepam, loroartecole , lipresin, lysine, macrogol 3350, magnesium, magnesium carbonate, magnesium chloride, magnesium hydroxide, magnesium oxide, magnesium sulfate, malathion, mangafodipir, manganese, mannitol, maprotiline, maraviroc, mebendazole, mebeverin, mecasermin, mecillinam, meclozin, medroxyprogrestron, medroxyprogrestron acetate, mefloquine, mefruside, megesterol, megesterol acetate, melatonin, melphalan, meloxicam, melperon, melphalan, memphine, memantine meningococpolysaccharide,), menotropin (hmG), mepensolar, mepivacaine, meprobamate, mepyramine, mercaptamine bitartrate, mercaptobenzothiazole, blend of mercapto, mercaptopurine, meropenem, mesalazine, methanol, metformin, metformin, mestolene, metformin , methionine, metolazone, methotrexate, methoxy polyethylene glycolepoetin beta acid, methylaminolevulinate, methyldopa, methylergonemtrine, methylergotamine, methylnaltrexone, methylnaltrexone bromide, methyloperone, methylphenidate, methylprednisolone, methylpredinizone acetate, methylpredinizole succinate, methylcoscolamine, methylprilone, metixen, metoclopramide, metopimazine, metoprolol, metronidazole, metychlotiazide, mexiletine, mexilazoline, miminamine , mitomycin, mitotane, mitoxantrone, mivacurium, moclobemide, modafinil, molybdenum, mometasone furoate, moroctocog alfa, morphine, moxaverin, moxifloxacin, moxonidine, mupirocin, mycophenolic acid, mycophenolate mofetil, nabumetone, nadolol, nafarelin, nalbuphine, nalidixic acid, naloxone, nalterexone, nandrolone, naphazoline, naproxen, natrapine namlinline , neomycin, neomycin sulfate, neostigmine, nepafenac, nevirapine, nicheritrol, nickel, nicomorphine, nicorandil, nicotine, nicotinamide, nicotinic acid, nicotinic acid / laropiprant, nicotinyl alcohol, nifedipine, nilotinib, nimodipine, nifedipine, nitisinone, nitrazepam, nitrendipine, nitric oxide, nitrofurantoin, nitrogen, nitric oxide (org .: nitrogen oxide), nitroprusside, nizatidine, nonacog alfa, norepinephrine, norelgestromin, norelgestromin / ethinylestradiol, norethisterone acetate, norethisterone, norfloxacin, norgestimate, nortriptyline, noscapine, nystatin, olympoglate, ocotoxadate, oktotoxide olsalazine, omalizumab, omeprazole, ondansetron, opipramol, opium, oral cholera vaccine, orciprenaline, orlistat, ornidazole, ornithine, orphenadrine, oseltamivir, osteogenic protein-1: BMp-7, oxaliplatin, oxazepa, oxazepam, oxacarbezepine, oxymetolone, oxyphencyclimine, oxytetracycline, oxseprenolol, oxybutynin, oxycodone, oxygen, oxymetazoline, oxytetracycline, oxytilphonone, pallitaxine, pallitaxine panitumumab, pantoprazole, pantothenol, vitamin B5, pantothenic acid, papaverine, paracetamol, paraffin oil, parathyroid hormone (rDNA), parecoxib, paricalcitol, paroxetine, pegaptanib, pegaptanib sodium, peglifilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed, penciclovir, penfluridol, penicillamine, pentaerythritolitrite, pentaerythritolital peridizine, perindopril, permethrin, perphenazine decanoate, perphenazine, pertussis toxoid, pethidine, pethidine, phenazone, phenazone salicylate, fenemal, fenfluramine, phenobarbital, phenoperidine, phenoxymethylpenicillin, fenoprocumone, fentanyl, pentolamine, phenylamine, phenylbutazone, phenylephrine, phenylpropanolamine, phenytoin, phosphate, phosphestrol, phytomenadione, vitamin K1, phytominadione, pilocarpine, pimecrolimus, pimozogazonazonazonolazonol metformin, pipamperon, piperacillin, pyrithrimid, piroxicam, pivampicillin, pivalecilam, pizotifen, pizotifen, plasminogen, plerixafor, podophyllotoxin, polidocanol, polyesterdiol phosphate, polygleline, polymyxin B, polythiazide, posaconazole, potassium, potassium acetate, potassium chloride, potassium dihydrogen phosphate, potassium dichromate, potassium hydroxide, potassium phosphate, p-phenylenediamine, pramipexole, prasugrel, pravastatin, predisone , prednisone, pregabalin, prearterlet, prilocaine, primidone, propantheline, probenecid, procaine, procainamide, procarbazine, prochlorperazine, procyclidine, proethazine, progesterone, proguanil, proline, promethazine, propafenone, propantheline bromide, propionmazine, propofol, propranolol, propylthiouracil, propyphenazone, proscylaridine, protamine, protein C, human protein C, protein S, protriptyline, proxifylline, prucaroplyd, pseudoephalidene pyrazinamide, pyridostigmine, pyridoxine, pyridoxine, vitamin B6, pyritildion, pirvinium (org .: pyrvin), quetiapine, quinagolide, quinapril, quinine, a mixture of quinoline, rabeprazole, raffinose, raloxifene, raltegravir, ramipril, ranibizumab, ranitidine, ranolazine, rasagiline, rasburicase, reboxetine, recombinant retinol retine. , reteplase, retinol, retinol, vitamin A, ribavirin, riboflavin, vitamin B2, rifabutin, rifampicin, rimiterol (org .: riiterol), rilonacept, riluzole, rimexolone, rimonabant, risedronate, risperidone, ritonavir, rituximab, rivaroxaban, rivastigmine, rizatriptan, rocuronium, romiplostim, ropinirole, ropivacitazone, rosiglitigone , rufinamide, Sagrada extract, salazosulfapridin, salazosulfapridine, salbutamol, salicylic acid, salicylamide, salmeterol, lexidroniam samarium pentasodium [153 sm], sapropterin, saquinavir, saxagliptin, scopolamine, selegiline, selenium, selenium disulphide, senna glycosides, serine, sertindole, sertalin, sevelamer, sevelamer (carbonate), sibutramine, sildenafil, simethicone (activated dimethicone), simvastatin, sitaglicin, sitagliptin phosphate monohydrate / metformin hydrochloride, sitaxentan, sitaxentan sodium, s-ketamine, sodium oxybate, sodium phenylbutyrate, sodium cromoglycate, auranofin sodium aurothioate, Sodium picosulfate, solifenacin, solvsulfadiazin, somatropin, somatrem, somatropin, sorafenib, sorbitol, sotalol, spectinomycin, spiramycin, spironolactone, stanozolol, stavudine, stiripentol, streptokinase, strontium renelinate, sucralfazam, sulfamate, sugules sulfasalazine, sulfate, sulfosomidine, sulfur hexafluoride, sulpiride, sumatriptan, sunitinib, suxamethonium, syntostigmin, tacrolimus, tadalafil, tafluprost, tamoxifen, tamosulosin, tasonemrin, taurine, tazobactam, tegafur, teicoplanin, telbivudine, telithromycin, telmisartan, telmisartan / hydrochlorothiazide, temoporfin, temozolomide, temsirolimus, tenecteplase, teniposide, tenofoviline teroxipine , testosterone enantalum, testosterone undecanoate, tetanus toxoid, tetrabenazine, tetracosactide, tetracycline, tetrisoline, thalidomide, theophylline, Ethylenediamine, Theophylline, Thiamisole, Thiamine, Vitamin B1, Thiethylperazine, Thioguanine, Thiomersal, Thiopental, Thioridazine, Thiotepa, Thiotixene, Threonine, Human Thrombin, Thyrotropin Alpha, Taigabine, Thiamazole, Thiamine, Thi tyklycinic acid. , tinzaparin, tiotropium, tipranavir, titanium dioxide, tizanidine, tobramycin, tocilizumab, tocofersolan, tocopherol, vitamin E, tocopherol, tolazamide, tolbutamide, tolcapone, tolfenamic acid, tolterodine, tolvaptan, topiramate, topotecan, toremifene, trabectedin, tramadol, trandolapril, tranexamic acid, trastuzumab, travoprost, travoprost, travoprost / timolol, treosulfan, treprostilin, triacelluvax, triamcinolone, triamcinoprimethimethimethimidone, , trimipramine, triptorelin, thrombin, tropicamide, tropisetron, triospium chloride, tryptophan, thyrotropin, uliprystal, ulipristal acetate, urofolitropin (uFSH), urokinase, ustekinumab, valaciclovir, valdecoxib, valganciclovir, valine, valproate, valsartan, vancomycin, vardenafil, varenicline, varenicline tartrate, vasopressin, venlafaxine, verapamil, verteporfin, vigabartin, vildforminline , vincristine, vindesine, vinfluine bitartrate, vinorelbine, zonisamide, zopiclone, zuclopenthixol, zuclopenthixol acetate, zultopenthixol decanoate, zuclopentizol, αΐ-protease inhibitor (human), α-amylcinnamaldehyde and combinations thereof. Pharmaceutical compositions may be prescription or non-prescription substances, such as vaccines. Non-limiting examples of vaccines include characterized viable autologous cartilage cells expanded ex vivo containing specific marker proteins, combined diphtheria, tetanus, acellular component of pertussis and recombinant hepatitis B vaccine, combined hepatitis A and B vaccine, diphtheria vaccine, tetanus pertussis, hepatitis B, conjugate vaccine against H. type B influenzae, diphtheria, tetanus, full cell pertussis and hepatitis B vaccines, diphtheria, tetanus, acellular component of pertussis, hepatitis B recombinant (adsorbed), inactivated poliomyelitis vaccine and adsorbed conjugate against H. type B influenza, vaccine against diphtheria, tetanus, acellular component of pertussis, hepatitis B recombinant (adsorbed), inactivated vaccine against Haine-Medina disease, influenza B conjugate (meningococcal protein conjugate) and hepatitis B vaccine (recombinant) hepatitis A (inactivated), hepatitis B antigen (rDNA) (HAB) (adsorbed), hepatitis B vaccine (rDNA) (adjuvant, adsorbed), hepatitis B vaccine (recombinant), against human papillomavirus, human papillomavirus [types 6, 11, 16, 18] (recombinant, adsorbed), human rotavirus, containing live attenuated virus, inactivated hepatitis A virus HBsAg recombinant, purified, influenza vaccine (split virion, inactivated) , influenza vaccine (surface antigen, inactivated, prepared in cell culture), Japanese encephalitis vaccine (inactivated, adsorbed), (live) vaccine against measles, mumps and rubella, vaccine (live) against measles, mumps, rubella and chickenpox, pandemic influenza vaccine, pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvant); A / California / 7/2009 (H1N1) v type strain (X-179A), pandemic influenza vaccine (surface antigen, inactivated, adjuvant); A / California / 7/2009 (H1N1) v type strain (X-179A), pandemic influenza vaccine (whole virion, derived from VERO cells, inactivated), conjugated vaccine (adsorbed) against pneuomococcal polysaccharides, conjugated pneumococcal saccharide vaccine, adsorbed, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvant) A / Vietnam / 1194/2004 NIBRG-14, rotavirus vaccine, (live) vaccine against herpes zoster and combinations thereof.

[0051] Over-the-counter substances may be vitamins or their derivatives, mineral compounds or their derivatives. The vitamin or mineral compound may be thiamine, thiamine pyrophosphate, riboflavin, flavin mononucleotide, flavinoadenine dinucleotide, niacin, nicotinic acid, nicotinamide, niacinamide, nicotinamide adenine dinucleotide, tryptophan, biotin, retin acid, folic acid , beta-carotene, 1,25-dihydroxycholecalciferol, 7-dehydrocholesterol, alpha-tocopherol, tocopherol, tocotrienol, menadione, menaquinone, phylloquinone, naphthoquinone, calcium, calcium carbonate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, citrate citrate, calcium gluconate, calcium lactate, calcium phosphate, calcium levulinate, phosphorus, potassium, sulfur, sodium, sodium docusate, chloride, magnesium, magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, magnesium sulfate, copper, iodine, zinc, chromium, molybdenum, iron carbonyl, iron fumarate, polysaccharide iron, their combinations and derivatives without restrictions. Derivatives of vitamin compounds include salts, alkali salts, esters and chelates of any vitamin compound without restrictions. Non-prescription substances can also be herbal compounds, herbal extracts, their derivatives or combinations without restrictions.

[0052] The pharmaceutical composition may be in any form and combinations thereof. Examples of these forms include, without limitation, chewable tablets, fast dissolving tablets, effervescent tablets, reconstituted powder, elixir, liquid, solution, suspension, emulsion, tablet, multilayer tablet, bilayer tablet, capsules, soft gelatin capsules, hard gelatin capsules, caplets, pastilles, chewable pastilles, granules, powder, granules, dispersible granules, sachets, irrigators, suppositories, cream, ointment, inhalers, aerosol inhalers, plasters, particle inhalers, implants, implant depot, dragees, ampoules, for ingestion, injection, infusion, health strip, liquid, food, nutrients, functional food, yogurt, gelatin, cereal, cereal coating, feed for animals and their combinations. Preparations of any of the above forms may be prepared by techniques and methods well known and readily available to those familiar with the state of the art.

[0053] The previously described object and many other purposes are intended to be realized in the third aspect of the invention by providing a method of accessing the elements in sequential order comprising: providing a blister pack according to the second aspect of the invention and administering it to the animal.

[0054] An animal is defined herein to refer to all members of the animal kingdom, including humans.

[0055] In some embodiments of the third aspect of the invention, the animal is a woman, e.g., pregnant, nursing, menopausal, women preparing to conceive, or using contraceptive compositions.

[0056] The method of the present invention may be used by any human or other animal. The present method is particularly suitable for individuals with particular therapeutic needs or specific therapeutic needs, especially when these needs would benefit from a complex treatment regimen. For example, but not limited, the present method is particularly suitable for menopausal women, lactating women, pregnant women, men or women planning to conceive a child, persons suffering from a pathological condition or any combination of the above.

[0057] The subject of the present invention includes a method for providing optimal therapeutic support to an animal by increasing compliance with a complex dosage regimen and facilitating the simultaneous administration of incompatible substances in storage. The subject of the present invention also includes a method for increasing patient compliance with prescription drug substances.

[0058] The prescription substance can be, without limitation, a hormone replacement therapy agent, a contraceptive, an anti-osteoporosis agent, a chemotherapeutic agent, an anti-infective agent, an analgesic, a steroid, an appetite suppressant, a slimming agent, a tobacco antagonist, a cholesterol lowering agent or combinations. A prescription drug substance can mean a treatment regimen, a complex daily treatment regimen.

[0059] The methodology of the subject of the present invention is not strictly limited to the blister pack. Any conventional pharmaceutical container (s) with structural similarity to blister packaging are suitable. Non-limiting examples of containers include tubes, canisters, packages and the like.

[0060] After describing the invention in this way, it will be obvious that it can be changed in different ways in the same way. Such variants should not be construed as departing from the nature and scope of the invention, and all such modifications are intended to fall within the scope of the appended claims.

[0061] The methods of the invention may also include providing marks on the blister pack according to the second aspect of the invention.

[0062] Although the present invention has been described in connection with certain embodiments, it should not be construed as being limited in any way to the examples shown. The scope of the present invention is defined by the accompanying set of claims. In the context of the claims, the terms "comprising" or "includes" do not exclude other potential elements or steps. Also, referenced references such as [articles in English] English in the singular] "a" or "an" etc. should not be interpreted as excluding the plural. The use of reference signs in the claims in relation to the elements indicated in the figures should also not be construed as limiting the scope of the invention. Furthermore, the individual features listed in the various claims can potentially be advantageously combined, and listing these features in the various claims does not exclude that a combination of features is not possible and advantageous.

[0063] The first, second and third aspects of the present invention may each be combined with any other aspects. These and other aspects of the invention will be obvious and explained with reference to the embodiments of the invention described below.

[0064] A number of preferred and / or optional features, elements, examples and methods of implementation will be summarized below. The features or elements described in relation to one embodiment or aspect may be combined with or applied to other embodiments or aspects, as appropriate. As an example, the feature or element described in relation to the opening system may be implemented as a method step, if applicable. Also, explanations of the basic mechanisms of the invention as used by the applicants are provided for explanation, and should not be used in the ex post facto analysis to explain the invention.

BRIEF DESCRIPTION OF THE FIGURES [0065] The system according to the invention will now be described in more detail with reference to the accompanying figures. The figures show some embodiment of the present invention and are not to be construed as limiting to other possible embodiments of the invention falling within the scope of the appended claims.

Figure 1 shows a side view of a blister pack according to one embodiment of the invention.

Figure 1a shows a side view of a blister pack according to one embodiment of the invention after removing the first opening element, allowing access to the first recess.

Figure 2 shows a front view of a blister pack according to one embodiment of the invention.

Figure 2a shows the opening order according to the embodiment of the invention in figure 2.

Figures 2b, 2c and 2d show other embodiments of the invention with a different opening order.

Figure 3 shows a front view of a blister pack according to another embodiment of the invention.

Figure 4 shows a side view of a blister pack according to another embodiment of the invention.

Figure 4a shows a side view of a blister pack according to one embodiment of the invention after removing the first cover sheet, allowing access to the first cavity.

Figures 5 and 5a show a side view of a blister pack according to one embodiment of the invention, in which the carrier sheet comprises a rigid structure.

Figures 6 and 6a show a side view of a blister pack according to one embodiment of the invention, in which the carrier sheet comprises a rigid structure and the carrier has at least one depression on top and at least one depression on the bottom surface of the carrier.

Figure 7 shows a front view of a blister pack according to another embodiment of the invention, including a gripping flap.

Figures 8a, 8b and 8c show different flap shapes that can be used for a better grip of the cover sheet.

Figures 9, 10 show blister packs according to other embodiments of the invention.

Figure 11a schematically shows a top view of an embodiment of the invention.

Figure 11b shows various embodiments with different arrangements of the flaps and cavities.

Figures 12a and 12b schematically show a top view of an embodiment of the invention in which a portion of the cover sheet is removed during or after the perforation process.

Figure 13a schematically shows a top view of an embodiment of the invention in which parts of the cover sheet are left unadhesive.

Figure 13b shows a cross-section of the embodiment of the invention of Fig. 13a.

Figure 14a schematically shows a top view of an embodiment of the invention in which the carrier sheet is in an unfolded state.

Figure 14b schematically shows a 3-D view of the embodiment of the invention of Fig. 14a in its assembled condition.

Figures 15a, b, c, d show an alternative embodiment of the invention based on the same folding principle as in figures 14a and 14b.

Figures 16a and 16b schematically show a 3-D view of the embodiment of the invention of Figures 15a, b, c, d before and after mounting the support ring, respectively.

Figures 17a, b, c and figures 18a and 18b schematically show a top view and a 3D view of an embodiment of the invention with a built-in closing lid.

Figures 19-23 show examples of packaging in which the arrangement of the cavities on the surface of the carrier sheet can provide an optimal structure to increase the rigidity of the packaging and to support the sequential desired opening.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION [0066] Figure 1 shows a side view of a blister pack according to one embodiment of the invention. A blister pack containing a series of 4 cavities in its carrier sheet is shown. This is for descriptive reasons and should not be interpreted as limiting the scope of protection. Any commercially convenient number of cavities can be made in a single blister pack.

[0067] The blister pack is characterized by a carrier sheet 1 in which at least two, but preferably a plurality of cavities 2-5 of carrier sheet 1 extending from the plane of carrier sheet 1 are present therein for accommodating pharmaceutical compositions in various forms, e.g. capsules, tablets or pills.

[0068] The blister pack also includes a series of cover sheets 6-9 at least partially attached to the carrier sheet 1 and around the respective cavities 2-5, with the function of controlling access to the cavities 2-5 housing the pharmaceutical compositions.

[0069] Covering sheets 6-9 are characterized in that the previous sheet is partially overlapped on the next, so as to provide predetermined and sequential access to cavities 2-5 and thereby to the pharmaceutical compositions contained therein.

[0070] In some other embodiments (not shown) the previous covering sheets fully overlap the next.

[0071] The carrier sheet 1 may also have one or more wells 10-13 adjacent to each respective well 2-5. In figure 1 the first recess 10 is shown as a stepped recess with the function of leaving a small part of the edge of the cover sheet 6 not adhered. From here, tab 14 is created.

[0072] By gripping the tab 14 of the cover sheet 6 and by peeling or tearing the tab 14, the cover sheet 6 is pulled up and back in accordance with arrow 18 and thereby removed, providing access to the first cavity 2 containing the pharmaceutical composition.

[0073] After removing the cover sheet 6, as shown in figure 1a, the recess 2 is open and access to the fold 15 is obtained, i.e. the overlapping area between cover sheet 6 and 7, to remove the cover sheet 7. A second recess 11 may be present to allow the tab 15 to be grasped so that by peeling or tearing the tab 15 the cover sheet 7 is pulled up and back in accordance with arrow 19 and the cover sheet 7 is removed, providing access to the recess 3 and so further.

[0074] While they are shown as wells in the carrier sheet in this example, the well areas may have different shapes and forms.

[0075] In another embodiment, one or more depressions may not be present, such that gripping of the cover sheets may be possible by leaving a small portion of the cover sheet not adhered around part of the edges of the respective depressions. The small portion may generally correspond to the overlapping area between the cover sheets or overlap present in the above embodiment.

[0076] Figure 2 shows a blister pack according to one embodiment of the invention.

[0077] While 16 recesses were shown in this embodiment, this was done for descriptive reasons and should not be construed as limiting the scope of protection. Any number of recesses in a single blister pack produced for commercial reasons is possible. Fig. 2 shows a front view of the package of Fig. 1. Access to the various recesses is obtained in a sequence that can be set in advance by providing a specific overlap of the cover sheets. As shown by Figures 1 and 1a, overlapping areas 15-17 between cover sheets 6-9 define the access sequence. Fig. 2 also shows cover sheet 20 and tab 21. Cover sheet 9 impedes access to tab 21, so that removal of cover sheet 9 occurs after removal of cover sheet 20 allowing access to recess 22. Accordingly, the cover sheet 23 can be removed by peeling or tearing the tab 24, which can only be accessed after removing the cover sheet 20. In Fig. 2a, the order of access to several cavities, according to arrow 25, is obtained by applying overlap between cover sheets and fold as shown in fig. 2.

[0078] Several opening directions can be obtained in a predetermined overlapping order, e.g. around, zigzag, top down, left to right. Two examples are shown in Figs. 2b and 2c in accordance with arrows 26 and 27, respectively. A third example showing the plurality of start points indicated by arrows 28-31 is shown in Fig. 2d.

[0079] Figure 3 shows a blister pack according to a further embodiment of the invention, in which the first covering sheet 33 has an overlap 32 which extends beyond the edge of the carrier sheet 37 (Figure 4). This allows the patient to grip without requiring a cavity.

[0080] In another embodiment, the patient grip for the first cover sheet of the blister pack can be achieved by using a cover sheet that does not extend beyond the edge of the support sheet and by leaving a portion of the cover sheet partially unadhesive along its edge.

[0081] As shown in the previous embodiment, access to the recess 34 is obtained by removing the cover sheet 33 by gripping and pulling, and thereby peeling / tearing the fold 32. As shown in Figs. 4 and 4a, removing the cover sheet 32 ​​provides also access to the next tab 35 to remove the next cover sheet 36.

[0082] In another embodiment of the invention, the blister pack carrier sheet comprises a rigid structure as shown in Figs. 5, 5a and 6, 6a. A rigid structure can mean a structure with a feature of stiffness, with a certain degree of stiffness, no bendability and lack of flexibility to enable safe handling in transport, e.g. via regular mail, avoiding undesirable tearing. The recesses can be produced by another technique, e.g. extrusion, injection molding, calendering, casting and other thermoplastic or pressure treatment, and the cavities between the cavities may be present (Fig. 5) or not (Fig. 5a).

[0083] In some embodiments of the second aspect of the invention, the at least one cavity adapted to contain pharmaceutical compositions on top and the at least one cavity adapted to contain pharmaceutical compositions on the bottom surface of the carrier sheet are spaced offset from each other in an interlocking manner.

[0084] In some other embodiments of the second aspect of the invention, the carrier sheet comprises at least two pivotally connected halves, each comprising one cavity adapted to contain pharmaceutical compositions, and wherein at least two halves are made of one single sheet consisting of a folded configuration, thus providing a rigid structure.

[0085] In some embodiments, the at least one recess on one of the at least two halves of the carrier sheets is arranged with an offset with respect to at least one recess on the other of the at least two halves, such that the recesses engage when the two halves are folded for complex configuration.

[0086] In other embodiments, the rigid structure means a solid block of material, e.g., the structure between the cavities is not hollow. For example, in Fig. 5, carrier sheet 48 can mean a block of material, i.e. a hard and solid piece of material.

[0087] In some other embodiments, the carrier sheet has at least one depression on top and at least one depression on its bottom surface as shown in Figure 6.

[0088] In some embodiments, the rigid structure is or comprises a hollow structure. In some embodiments, the rigid hollow structure may be filled inside with air or other gases, e.g., inert gases. For example, in Fig. 6 the carrier sheet 49 is a hollow rigid structure, i.e. no material is present between the carrier cavities. When the structure is hollow, support means may be present to provide stiffness, e.g. supporting elements 50-57 in Fig. 6a.

[0089] In some embodiments, at least two cover sheets are protected by at least one cover. In the description, the cover is defined as a removable layer, foil, rigid sheet, panel or hollow body that protects the covering sheet from undesirable tearing.

[0090] In some other embodiments, the lid may also include a patient information leaflet, e.g., instructions on how to use the pharmaceutical compositions contained, or advertising of related drugs.

[0091] In some other embodiments, this patient information may be printed, embossed, carved, stamped or etched on the inner or outer surface of at least one cover.

[0092] At least one cover may be made of plastic, plastic laminates, plastic / paper laminates, or plastic / metal or metal foil laminates. Non-limiting examples of suitable plastics for a carrier sheet are laminates containing PVC, polyamides, polyolefins, polyesters, polycarbonates, Teflon and combinations thereof. At least one cover may also be made of a material that is at least partially transparent in the visible light range to allow visual inspection of the pharmaceutical composition contained in the cavities of the carrier sheet.

[0093] In some embodiments, at least one cover is fully removable. In other embodiments, the at least one cover may be opened by rotating the cover along the at least one rotary joint located on the carrier sheet.

[0094] In some other embodiments, at least one cover is or comprises at least one adhesive element, such as a long thin piece of plastic, material or paper with binding properties, e.g. a piece of tape. In these embodiments, access to the cover and the carrier sheet can be obtained by rotating the cover along one of the edges of the carrier sheet.

[0095] Several cover sheets are not shown providing access to the recesses according to the opening system according to the invention for the packages shown in Figures 6 and 6a only for the sake of simplifying these figures.

[0096] In some embodiments, the carrier sheet further includes at least two peripheral regions, each at least partially surrounding half of the carrier, the peripherals protruding in a direction perpendicular to the covering sheet and being adapted to engage with each other when the blister pack is closed .

[0097] In some other embodiments of the inventor, the outer film is attached to the areas adjacent the periphery, with the surface of the carrier sheet constituting the outer surface of the package when the package is closed.

[0098] In some embodiments, the rigid structure may e.g. be obtained by the support 210 as shown in figures 14a and 14b. Carrier 210 can be produced in a single sheet of film in which two halves 211, 212 each containing cavities 207 arranged in rows can be identified. Figure 14a and Figure 14b show the carrier 210 in an unfolded and folded condition, respectively. The two halves 211, 212 are adapted to fold in such a way that the cavities 207 intertwine and thereby provide both rigidity and compactness to the carrier 210. The carrier 210 is preferably folded along two fold lines 213, so that the closed end of the cavity 207 houses on the opposite half, i.e. the closed end of the cavity 207 of half 211 is in half 212 and vice versa, as shown in figure 14a according to arrows 230. Such a design results in a carrier 210 in which the pharmaceutical compositions are to be accessible from both sides of the carrier 210. The cavities 207 are covered with a cover sheet 208 as described above; preferably the same covering sheet covers both halves 211, 212; it may also be that two separate cover sheets cover each half 211, 212. Cover sheet 208 is preferably glued to carrier 210 prior to folding, but it may, in principle, also be secured after folding carrier 210. In figures 14a and 14b, the cavities 207 are honeycomb shaped and are arranged in two rows on each half 211, 212 of the carrier 210. This configuration provides additional rigidity to the flexible blister structure when folded. Generally, in the folded state, the closed lower portion of the cavities 207 of half 212 may support the corresponding area in half 211 and vice versa. Any other shapes of interwoven cavities that can support the carrier sheet and provide rigidity to the final structure can be considered. Furthermore, the rigidity and thereby protection of the pharmaceutical compositions arranged in cavities 207 is provided by edge portions 214 formed to provide barrier and support to the carrier sheet along the edge of the carrier 210 after folding. Other shapes and arrangements for the same purpose are also within the scope of the present invention. The fact that the two halves 211, 212 are made of one folded sheet of material instead of the use of two separate sheets means that they are kept in a more constant relationship that adds rigidity to the carrier 210. To prevent the carrier 210 from decomposing, the two halves 211, 212 carrier 210 can be joined, e.g., by adhesive strips 215, such as hot melt adhesive. Such a connection will additionally prevent the two halves 211, 212 from moving together and thus also provide additional rigidity to the carrier 210.

[0099] Furthermore, the arrangement of the cavities on the surface of the carrier sheet can be optimized, e.g. by trial and error, to provide an optimal structure supporting the rigidity of the package and the desired subsequent opening. For example, figures 19-23 show examples of packaging in which the arrangement of the recesses on the surface of the carrier sheet can provide an optimal structure to increase the rigidity of the package and to support the next desired opening, e.g., by numbered recesses. For example in fig. 19, another arrangement of the cavities, e.g. 301 and 302, may also be combined with another location and section design, e.g. 304, for removing the cover sheet and providing access to the cavity underneath. 303 identifies the glued area connecting the upper and lower surfaces of the carrier sheet carrying blisters, e.g. 301 and 302. Figures 20 and 21 show two embodiments of a drug package, with cavities and scraps of an alternative shape. In Figure 21, small protrusions 305 are present between the cavities, e.g. 306 and scraps, e.g. 307.

[0100] Figures 22 and 23 show further embodiments of the invention for drug packaging with another combination of cavities, e.g. 308 or 310, and scraps, e.g. 309. Thus, sequential desired opening can be achieved.

[0101] Figures 15a, b, c, d show an alternative embodiment of the invention based on the same folding principle as in figures 14a and 14b. Figure 15a shows the unfolded carrier 210 in which the dashed lines 216 show the shape of the carrier 210 in figure 14a.

The embodiment of the invention in figures 15a, b, c, d is provided with protruding rims 217 along the edges. The sheet to be carrier 210 and the rims 217 are typically shaped by thermoforming a plastic sheet. After thermoforming to the shape of Figure 15a, the sheet is perforated along dashed lines 216 around two halves 211, 212 containing cavities 207. The two halves 211,212 are folded according to arrows 230 as shown in figure 14a to achieve the composite structure as shown in figure 15b which will leave the spaces between the rims 217 as holes. To obtain closed outer surfaces of the container, the outer film material 218, such as plastic film, is attached to the edge areas 217, preferably before folding. A total of outer film 218 and edge area 217, and thus to carrier 210, is shown in figure 15c, and the resulting view is observed from figures 15b and 15d in an open and closed state, respectively. In this way, the carrier 210 and thus the pharmaceutical compositions will be protected by sections 219 comprising rims 217 and an outer film 218 that will act as covers. If further rigidity and even a more closed design are desired, this can be achieved by adding another ring 220 on top of each edge 217. This is shown in figures 16a and 16b before and after mounting the ring, respectively. The ring 220 can be attached by any suitable means, such as by means of glue or accurate pressure.

[0102] In one embodiment of the invention, the carrier 210 including the periphery 217, according to the perforation along the dotted lines 216, filled with the pharmaceutical composition and additionally coated with the film 218 is folded without the separating rims 217 and the carrier 210. After opening, the blister pack foil 218 attached to the rim 217 will act as covers and the package will open along the dotted lines 216 which have been perforated after the thermoforming process. In this way, further rigidity of the structure is obtained, as the break along line 216 is only achieved after the first application of the packaging, in order to avoid unwanted opening during transport from the manufacturer to the first user of the packaging.

[0103] The first step in the presently preferred method of production, for example, the embodiment of figure 15a, b, c, d would be to shape the sheet containing the carriers 210 and the rims 217 to the geometry shown in figure 15a. This would typically be done by thermoforming a plastic sheet first. The cavities 207 are then filled with pharmaceutical compositions, and the cavities 207 are covered with a cover sheet 208, typically made of aluminum foil. The next stage is perforation when the carrier halves 211, 212 are separated from the edge areas 217. In the same or subsequent perforation step, the flaps 201 can be made as described previously, e.g. relative to figure 11a, b. Then outer film 218 is attached to the edge areas 217 as shown in figure 15c. The outer foil 218 can be glued and / or fixed e.g. by thermal welding or by gluing. Outer film 218 may mean a continuous film providing further protection to the cover sheet 208 so that no access to the cover sheet 208 is possible without removing the outer film 218 after opening the package.

[0104] In some embodiments, the outer film 218 may have the desired shape before being attached to the edge area 217, or it may be attached as a sheet of material covering a large number of containers, and therefore must be perforated to the desired shape after attachment.

[0105] All steps described up to this point can be carried out without having to rotate the material, which is advantageous from a manufacturing point of view. The following steps are preferably performed after rotating the containers 180 ° so that the underlying elements become the top side. If desired, an adhesive, such as hot melt adhesive strips, is used, and if desired, plastic rings 220 are thermoformed on top of the rims 217. The two halves 211, 212 of the carrier 210 are then folded together and joined, and the "covers" comprising the rims 217 with the outer film 218 are sealed around the carrier 210. If desired, instructions for using the pharmaceutical compositions within the container may be placed; they may e.g. be glued to the inside of the outer foil 218 before closing the container.

[0106] An alternative drug pack with a built-in closing lid will be described hereinafter with reference to figures 17a, b, c and 18a, b.

[0107] A blister package according to one aspect of an embodiment of the invention comprises at least four sections arranged in a row and made of a single sheet, each section pivotally connected to at least one other section along the fold line in a single sheet.

[0108] As a single sheet is meant a continuous sheet, e.g. plastic.

[0109] Each of the two middle sections of the at least four sections may be half of the carrier comprising at least one cavity adapted to contain pharmaceutical compositions, two halves of the carrier rotatably connected to each other. Each of the two end sections of the at least four sections may constitute an outer covering part for at least one half of the carrier, each of the two end sections pivotally connected to the corresponding half of the carrier.

[0110] Corresponding is defined herein as the complementary half of the carrier according to figures 17a, b, c and 18a and 18b.

[0111] The last four sections are adapted to fold into a folded configuration when the two halves of the carrier are stacked adjacent to each other with meshing recesses and with the open sides of the recesses facing each other.

[0112] In this way, each of the outer covering parts is positioned around half the carrier.

[0113] The design is based on the first step of thermoforming the plastic sheet to the shape shown in figure 17a. The sheet comprises a carrier sheet comprising two carrier halves 211, 212 corresponding to those of figure 14a. The sheet further includes at the two distal ends of the carrier half 211, 212 two outer covering parts 221. These portions 221 are an extension of half of the carrier when thermoforming was performed to form the periphery, but not the cavity for holding the pharmaceutical compositions. This can be considered as an advantage that thermoforming of a single film of plastic material can be carried out to identify parts having different functions, e.g. after housing the pharmaceutical composition or to provide further protection to the cover sheet protecting the cavities without having to change its orientation. The plastic sheet is then folded into the container as shown schematically in the side view of figure 17b by folding along fold lines 222 shown in figure 17c. In the folded state, the blister pack shows only two covering parts 221 as shown in figure 18a. When ready for use, it is possible to access one side of the carrier 210 only by opening one of the outer cover parts 221 (not shown). Figure 18b shows the container in a state where both outer cover parts 221 are partially open. An advantage of this embodiment of the invention is that the carriers 210 and the outer cover parts 221 are made of the same sheet of material and no further cover elements except for the cover sheets are needed to cover the pharmaceutical compositions in cavities 207.

[0114] In some embodiments, a larger capacity drug pack can be obtained by arranging more than two halves of the carrier in a row, which halves are then folded together and preferably glued in a two-by-two arrangement. Thus, double, triple or multiple structures can be obtained in which each two halves of the carrier can be combined in a two-by-two arrangement. In this configuration, two distal ends, i.e. the outer covers provide coverage for the outermost halves of the support.

[0115] In a multiple structure, subsequent opening can be achieved as described for a single structure. Another advantage may be that a package with an increased number of cavities is provided for holding pharmaceutical compositions.

[0116] In some embodiments, the non-adhesive tab that provides a better grip for peeling or peeling off the cover sheet and accessing the depressions may be a flap, e.g. a strip or scrap. Fig. 7 shows a blister pack according to another embodiment of the invention which includes a flap.

[0117] The specific contour of the flap is combined with its function. The flap can have any form and size that allows a person or machine to grasp the method described in the invention and to peel or peel off. While in this embodiment the element is shown to be triangular, in other embodiments it may take other forms, e.g. round or square.

[0118] Figures 8a, 8b and 8c show different shapes of the flap holder that can be used to better grip the cover sheet.

[0119] In some embodiments, an element such as a flap can be made of a non-slip material such as rubber or which may have some degree of roughness to provide a better grip and easier gripping and tearing or peeling.

[0120] In some other embodiments, it may be a user-friendly shape, e.g., pad-like, to provide a better grip for the user when used.

[0121] The flaps in this embodiment are shown on the specific edge of the cover sheet. In other embodiments, they may be located at a different location along the edges of the cover sheets.

[0122] By placing the flaps in different areas of the cover sheets, different opening order is possible.

[0123] In some other embodiments, the first flap may have a closing function, and thus, after removing the first flap, access to the next flap and cover sheet without exposing the first recess on the carrier sheet.

[0124] While the number and form of the recesses in the packaging are shown in a specific form, i.e. 16 cylindrical recesses, in other embodiments, the packaging may have more or less recesses and may have other forms, e.g. cubic, pyramidal or spherical.

[0125] Fig. 11a schematically shows a top view of an embodiment of the invention in which the flap 201 is provided next to each cavity 202. The flaps 201 are obtained by leaving areas under each flap 201 not adhered during manufacture when the cover sheet is attached to the carrier. In a preferably subsequent process step, the edges 203 of the flaps 201 are separated from the adhered portion 204 of the cover sheet, typically by perforation. The perforation can only pass through the cover sheet or fully or partly also through the support. The advantage of perforation only through the cover sheet is that the carrier is left intact and is thus more rigid and less prone to malfunction. The advantage of allowing full or partial perforation by the carrier is that tolerances for perforation tools and perforation performance may be less stringent. FIG. 11b shows various embodiments of the invention with different arrangement of flaps and cavities.

[0126] In an alternative embodiment to that shown in figures 11a and 11b, selected parts of the cover sheet are removed during or after the perforation process. An example of such an embodiment of the invention is schematically shown in figures 12a and 12b. Part of the cover sheet to be removed is indicated by 205 in the figures. This process may result in the tabs 201 being easier to grasp. As shown in Figure 12b, the cover sheet may extend beyond the edges of the carrier e.g. by an amount corresponding to the size of the flaps 201 and parts 205 of the cover sheet to be removed. Thus, the flaps 201 may even be easier to grasp than when they overlap the carrier.

[0127] In yet another embodiment of the invention shown schematically in Figures 13a and 13b, parts of the cover sheet are left unattached to the carrier as in the embodiment of Figures 11a and 11b. The embodiments differ in that in the one shown in Figures 13a and 13b, the manufacture does not include providing flaps 201 by perforation. Instead of ego, a recess 206 is placed next to each cavity 207, and to access the contents of the cavity, the cover sheet 208 is pressed against the cavity 206 and the cover sheet 208 is removed from above the actual cavity 207. This operation is typically performed with a finger 209, but appropriate tool. In this embodiment of the invention, the cover sheet 208 is preferably glued to the carrier over the entire non-cavity area

206 or cavity 207. An advantage of this embodiment of the invention is that no perforation step is necessary in the manufacturing process. Figure 9 shows a further embodiment of the invention in which the blister pack comprises four covering sheets 44-47, each providing multiple access to 4 cavities. For example, removing the cover sheet 44 by gripping, pulling up and back on tab 38 provides simultaneous access to recesses 39-42. In this way, multiple dosing of the pharmaceutical composition present in the wells is achieved, as several wells are made available by single removal of the cover sheet. Removal of the cover sheet 44 also provides access to the flap 43, which in turn allows the removal of the cover sheet 45 providing access to a further 4 cavities.

[0128] Multiple dosing can be very convenient for a particular disease. For example, this may be particularly advantageous as a convenient, simple and effective way to facilitate the simultaneous administration of incompatible substances in storage, especially when these substances are taken as part of a complex sequential daily treatment regimen.

[0129] Figure 10 shows a further embodiment of the invention in which the removal of the first covering sheet provides simultaneous access to the 2 depressions and to the flap for removing the next covering sheet. The advantage is also facilitating simultaneous prescription and over-the-counter administration as part of a complex regimen.

[0130] Although the present invention has been described in connection with certain embodiments of the invention, it should not be construed as limiting it in any way to the examples presented. For example, the carrier is described as being made by thermoforming a plastic sheet. However, other manufacturing processes, such as thermoplastic casting, are also within the scope of the present invention. Materials may also vary, so container parts may be made of, e.g., polymer foam, composite materials, or paper-based materials such as cardboard. Accordingly, joining methods other than those mentioned are included; such methods being well known to those skilled in the art. All embodiments of the invention may be provided with closing and opening means as shown in the figures. Other possible designs of closing and opening means remain within the competence of the person skilled in the art.